Investigating a new drug to prevent oral cavity cancers
CD 1530, an RAR Gamma Agonist for Oral Cavity Squamous Cell Carcinoma Prevention
This study is looking at a new drug called CD1530 that might help prevent a type of mouth cancer by changing how cells in the mouth behave, and it could lead to trials for patients to see if it works safely for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10927202 on NIH RePORTER |
What this research studies
This research focuses on the use of CD1530, a selective agonist for the retinoic acid receptor gamma (RARγ), to prevent oral cavity squamous cell carcinoma. The study aims to understand how this drug can alter the transcriptional profile of cells in the oral cavity to reduce the risk of cancer development. By utilizing a murine model, researchers have shown promising results in reducing carcinoma formation, indicating potential for human application. Patients may be involved in trials to assess the effectiveness and safety of this preventive treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for oral cavity squamous cell carcinoma, particularly those with a history of tobacco use or other risk factors.
Not a fit: Patients who have already been diagnosed with advanced oral cavity cancers may not benefit from this preventive approach.
Why it matters
Potential benefit: If successful, this research could significantly lower the incidence of oral cavity cancers, improving survival rates and quality of life for patients at risk.
How similar studies have performed: Previous research has shown success with similar approaches using retinoic acid receptor agonists in cancer prevention, suggesting a promising avenue for this study.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Gudas, Lorraine J — Weill Medical Coll of Cornell Univ
- Study coordinator: Gudas, Lorraine J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.